Antengene Corporation Limited

Antengene Corporation Limited, a biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. Its commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. The company also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, its pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, it develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.